Drugs / TBI-2001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05963217 | Jul 2023 → Jun 2028 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | University Health Network, Toronto | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TBI-2001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05963217 ↗ |
| Modality | Cell therapy | “TBI-2001 is a next-generation CAR-T product” NCT05963217 ↗ |
| Route | Intravenous | “0.3 to 3 x 10\^6 autologous CD19-CAR-T cells/kg per patient will be administered intravenously” NCT05963217 ↗ |